Impact of universal vaccination against chicken pox in Navarre, 2006-2010
Keywords:
Varicela. Vacunación.Abstract
Background. In 2007 universal vaccination against chicken pox was introduced in the vaccine calendar of Navarre. The aim of this study is to evaluate the impact of this measure on the incidence of chicken pox in both the vaccinated cohorts (direct effect) and in the unvaccinated cohorts (indirect effect). Methods. Chicken pox is a disease of individualized compulsory notification. We analyzed the annual incidence by age groups between 2006 and 2010. Hospital admittances with chicken pox or complicated chicken pox as the principal diagnosis were taken from the minimum basic data set on hospital discharges for the years 2006 to 2009. Results. The incidence of chicken pox has fallen by 93.0%, from 8.04 cases per 1,000 inhabitants in 2006 to 0.56 per 1,000 inhabitants in 2010 (p<0,0001). In children from 1 to 6 years (vaccinated cohorts), the incidence of chicken pox has fallen by 96.3%. In the cohorts vaccinated at 10 and 14 years, a fall of 93.6% can also be observed in children from 10 to 14 years, and of 85.0% in those of 15 to 19 years. In the unvaccinated age groups we can observe falls of 88.2% in children under one year, of 73.3% in those of 7 to 9 years, and of 84.6% in people over 20 years. In 2006 there were 25 hospital admissions due to chicken pox in Navarre and in 2009 this figure fell to 7. The rate of admissions fell by 71%. Conclusion. The introduction of universal chicken pox vaccination in Navarre has resulted in a rapid and very steep reduction of the incidence of chicken pox in both vaccinated and unvaccinated people.Downloads
References
1. SEWARD JF, WATSON BM, PETERSON CL, MASCOLA L, PELOSI JW, ZHANG JX et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287: 606-611.
https://doi.org/10.1001/jama.287.5.606
2. GROSE C. Varicella vaccination of children in the United States: Assessment after the first decade 1995-2005. J Clin Virol 2005; 33: 89-95.
https://doi.org/10.1016/j.jcv.2005.02.003
3. SEWARD JF, MARIN M, VAZQUEZ M. Varicella vaccine effectiveness in the US vaccination program: A review. J Infect Dis 2008; 197: S82-S9.
https://doi.org/10.1086/522145
4. MACARTNEY KK, BEUTELS P, MCINTYRE P, BURGESS MA. Varicella vaccination in Australia. J Paediatr Child Health 2005; 41: 544-552.
https://doi.org/10.1111/j.1440-1754.2005.00717.x
5. CARVILLE KS, RIDDELL MA, KELLY HA. A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine 2010; 28: 2532-2538.
https://doi.org/10.1016/j.vaccine.2010.01.036
6. BOOT HJ, DE MELKER HE, STOLK EA, DE WIT GA, KIMMAN TG. Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine 2006; 24: 6288-6299.
https://doi.org/10.1016/j.vaccine.2006.05.071
7. Boletín Oficial de Navarra. Orden Foral 133/2006, de 13 de diciembre, de la Consejería de Salud, por la que se modifica en Calendario Oficial de Vacunaciones de Navarra. BON núm 4, 08/01/2007. Boletín Oficial de Navarra 2007.
8. Agencia española de medicamentos y productos sanitarios. Ficha técnica de Varivax®, revisión 2008. Available from: https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaWordPdf&codigo=65709&formato=pdf&formulario=FICHAS
9. FOX J, ELVEBACK L, SCOTT W, GATEWOOD L, ACKERMAN E. Herd immunity: basic concept end relevance to public health immunization practices. Am J Epidemiol 1971; 94: 179-189.
https://doi.org/10.1093/oxfordjournals.aje.a121310
10. FOX J. Herd immunity and measles. Rev Infect Dis 1983; 5: 463-464.
https://doi.org/10.1093/clinids/5.3.463
11. Boletín Oficial de Navarra. Orden Foral 19/2008, de 15 de febrero, de la Consejería de Salud, por la que se modifican las enfermedades incluidas en el Sistema de Vigilancia Epidemiológica de Navarra. BON núm 28, 01/03/2008. 2008.
12. GARCÍA CENOZ M, CASTILLA J, MONTES Y, MORAN J, SALABERRI A, ELIA F et al. Varicella and herpes zoster incidence prior to the introduction of systematic child vaccination in Navarre, 2005-2006. An Sist Sanit Navar 2008; 31: 71-80.
https://doi.org/10.4321/S1137-66272008000100006
13. KWONG JC, TANUSEPUTRO P, ZAGORSKI B, MOINEDDIN R, CHAN KJ. Impact of varicella vaccination on health care outcomes in Ontario, Canada: Effect of a publicly funded program? Vaccine 2008; 26: 6006-6012.
https://doi.org/10.1016/j.vaccine.2008.08.016
14. SIEDLER A, ARNDT U. Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill 2010; 15 (13):pii=19530.
https://doi.org/10.2807/ese.15.13.19530-en
15. MULLOOLY JP, MAHER JE, DREW L, SCHULER R, HU W. Evaluation of the impact of an HMO's varicella vaccination program on incidence of varicella. Vaccine 2004; 22: 1480-1485.
https://doi.org/10.1016/j.vaccine.2003.10.021
16. KUPEK E, TRITANY EF. Impact of vaccination against varicella on the reduction of the disease incidence in children and adolescents from Florianopolis, Brazil. J Pediatr (Rio J) 2009; 85: 365-368.
https://doi.org/10.1590/S0021-75572009000400016
17. DAVIS MM, PATEL MS, GEBREMARIAM A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004; 114: 786-792.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2011 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
